“Compounded” weight-loss injections in the UK: what to check

“Compounded semaglutide” and “compounded tirzepatide” are often imported marketing phrases. In the UK, the useful questions are more exact: what product is being supplied, what is its authorisation status, who prescribed it, which pharmacy supplied it, and why was that route chosen?

Direct answer

Do not assume that “compounded” has one settled UK meaning. Ask whether the proposed injection is a named, UK-authorised medicine or an unlicensed medicine supplied for an individual clinical need. An unlicensed medicine is not automatically illegal, counterfeit or unsuitable, but it does not carry the same UK marketing authorisation as a licensed product and should come with a clear prescriber, pharmacy and clinical rationale.

Why the word “compounded” needs translating

Online promotion can borrow “compounded” terminology from other countries, particularly the United States. UK medicines law and professional practice do not map neatly onto US categories. The word on an advert therefore does not establish the product's legal status, quality controls or route of supply.

For a UK patient, “compounded” might be used loosely for a specially prepared product, an imported unlicensed medicine, or something whose status is not explained at all. The label is not enough. The provider should identify the exact preparation and say plainly whether it has a UK marketing authorisation.

Licensed and unlicensed are not synonyms for safe and unsafe

The MHRA says an authorised medicine has been assessed against standards of safety, quality and efficacy for its authorised uses. Its current public GLP-1 guidance identifies Wegovy and Mounjaro among licensed UK medicines and warns that not every product promoted as a weight-loss injection is authorised for that purpose.

An unlicensed medicine has no UK marketing authorisation and may not have been assessed by the MHRA. That distinction matters, but it does not mean every unlicensed medicine is unlawful or counterfeit. MHRA guidance recognises a tightly defined “specials” route for an individual patient when no available licensed medicine can meet that patient's clinical needs. The need must be clinical and is determined by the prescriber responsible for the person's care.

Counterfeit or falsified products are a different category again: they misrepresent identity, composition or source. A provider should not blur “unlicensed”, “special” and “falsified” into one warning label, nor use “bespoke” language to avoid answering basic product-status questions.

The UK hierarchy starts with a suitable licensed medicine

MHRA specials guidance says Regulation 167 of the Human Medicines Regulations 2012 permits unlicensed supply when no available licensed medicine can meet an individual patient's clinical needs. That is an exception to the normal requirement for a marketing authorisation, not a parallel consumer product category chosen simply because it sounds personalised.

The practical question is therefore: why is the authorised route not meeting this individual's clinical need? The answer should come from the accountable prescriber. A general claim about convenience, exclusivity or a product being “custom-made” does not explain the clinical rationale.

Use Wegovy and Mounjaro only as identity comparators

Current UK electronic Medicines Compendium records identify Wegovy products as semaglutide solutions for injection in pre-filled pens and Mounjaro KwikPen products as tirzepatide solutions for injection in pre-filled pens. Their SmPCs name the active substance, presentation, marketing-authorisation holder and authorisation numbers.

Those records provide a way to check product identity; they are not a treatment comparison and do not show that either medicine is right for a particular person. If a provider says it supplies “semaglutide” or “tirzepatide” but cannot give the product name, presentation and UK authorisation status, the claim is too vague to verify against the authorised product information.

What an online service and pharmacy should explain

The GPhC-backed guide to obtaining medicines or treatment online says the healthcare professional should explain treatment options in a way the patient can understand, prescribe only when it is safe to do so, provide written information about medicines and explain potential side effects. It also says patients should be told who is responsible for monitoring and further treatment, and whom to contact if they feel unwell or have follow-up questions.

For an unlicensed product, that ordinary transparency becomes especially important. Before paying, the service should be able to separate the prescribing business from the dispensing pharmacy, name the accountable prescriber, explain the product's status and give a usable after-care route. A polished clinic brand does not substitute for those facts.

Seven checks before trusting the claim

  • Exact product: what is the full product or preparation name and presentation?
  • Authorisation status: is it a UK-authorised medicine or an unlicensed medicine?
  • Clinical reason: if unlicensed, why can no available licensed medicine meet this patient's identified clinical need?
  • Named prescriber: who made and owns the prescribing decision, and can their UK professional registration be checked?
  • Supplying pharmacy: which registered pharmacy dispenses or supplies it, and do the register details match?
  • Written information: what product information, status explanation and side-effect information will accompany supply?
  • Follow-up: who handles monitoring, questions and problems after the medicine arrives?

If these questions produce only a brand name, testimonials or repeated “compounded” wording, the evidence gap remains. Our guide to checking a fake or cloned online pharmacy covers register and identity checks. The UK access guide for semaglutide and tirzepatide explains the wider prescribing and pharmacy trail.

Claims that deserve extra scrutiny

  • The service treats “compounded” as proof of higher quality, personalisation or better results.
  • The product is described only by an ingredient name, with no preparation, manufacturer or authorisation status.
  • No individual clinical reason is given for departing from an available licensed route.
  • The prescriber or supplying pharmacy cannot be identified before payment.
  • Public advertising makes an unlicensed medicine look like an ordinary retail product.
  • The provider relies on US regulatory language without explaining the UK route.

None of these points determines the facts of an unnamed product by itself. They show where the provider needs to supply verifiable information rather than reassurance.

Sources

  1. MHRA. Supply unlicensed medicinal products (“specials”). Read the current GOV.UK guidance.
  2. MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Read the GOV.UK guidance.
  3. General Pharmaceutical Council and UK health organisations. How to keep safe when getting medicines or treatment online. Read the guide (PDF).
  4. electronic Medicines Compendium. Wegovy — Summary of Product Characteristics. Read the current UK SmPC.
  5. electronic Medicines Compendium. Mounjaro KwikPen — Summary of Product Characteristics. Read the current UK SmPC.